Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.

Autor: Hashim PW; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Chima M; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Kim HJ; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Bares J; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Yao CJ; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Singer G; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Chen T; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Genece J; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Baum D; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Kimmel GW; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Nia JK; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Gagliotti M; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York., Lebwohl MG; Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: mark.lebwohl@mountsinai.org.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Feb; Vol. 82 (2), pp. 360-365. Date of Electronic Publication: 2019 Jul 03.
DOI: 10.1016/j.jaad.2019.06.1288
Abstrakt: Background: Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects.
Objective: To assess the safety and efficacy of crisaborole 2% ointment-a nonsteroidal phosphodiesterase 4 inhibitor-in the treatment of intertriginous, anogenital, and facial psoriasis.
Methods: A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS).
Results: After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events.
Limitations: The study was limited to a single tertiary care center and small sample size.
Conclusion: Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.
(Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: